College of Pharmacy, Hanyang University, Ansan, Gyeonggi-Do, Republic of Korea.
Pharmaceutical Research Centre, Hanmi Pharm. Co, Hwaseong, Gyeonggi-Do, Republic of Korea.
Pharm Dev Technol. 2021 Jun;26(5):576-581. doi: 10.1080/10837450.2021.1903036. Epub 2021 Mar 26.
The objective of this study was to develop a novel acetaminophen and tramadol hydrochloride-loaded soft capsule (ATSC) with enhanced bioavailability of tramadol. The ATSC was manufactured in a pilot-scale batch size with the capsule contents composed of tramadol, acetaminophen, PEG 400 and Capmul MCM at a weight ratio of 37.5:325:177.5:30. Moreover, its dissolution, stability and pharmacokinetics in beagle dogs were carried out compared to commercial tablet. The dissolved amounts of acetaminophen from the ATSC and commercial tablet were not significantly different. However, compared to the latter, the former had significantly higher dissolution rate of tramadol at the initial times. In beagle dogs, the ATSC provided no significant difference in plasma concentrations and AUC of acetaminophen than did the commercial tablet; however, it significantly improved those of tramadol compared to the other, indicating the enhanced oral bioavailability of tramadol. Compared to the commercial tablet, the ATSC had a larger AUC value for tramadol (55.27 ± 11.06 vs. 92.62 ± 21.52 h·ng/ml). In the accelerated long-term stability, the ATSC offered higher than 96% drug content of acetaminophen and tramadol, suggesting that it was stable for at least six months. Therefore, this ATSC would be a recommendable candidate with enhanced oral bioavailability and excellent stability.
本研究旨在开发一种新的含对乙酰氨基酚和盐酸曲马多的软胶囊(ATSC),以提高曲马多的生物利用度。采用中试批量规模制备 ATSC,胶囊内容物由曲马多、对乙酰氨基酚、PEG400 和 Capmul MCM 组成,重量比为 37.5:325:177.5:30。此外,与市售片剂相比,对其进行了溶解、稳定性和药代动力学研究。ATSC 和市售片剂中对乙酰氨基酚的溶出量无显著差异。然而,与后者相比,前者在初始时间具有更高的曲马多溶解速率。在比格犬中,ATSC 与市售片剂相比,对乙酰氨基酚的血浆浓度和 AUC 无显著差异;然而,与后者相比,它显著提高了曲马多的 AUC,表明曲马多的口服生物利用度得到了提高。与市售片剂相比,ATSC 曲马多的 AUC 值更大(55.27±11.06 与 92.62±21.52 h·ng/ml)。在加速长期稳定性研究中,ATSC 提供的对乙酰氨基酚和曲马多的药物含量均高于 96%,表明其至少稳定 6 个月。因此,这种 ATSC 将是一种具有增强的口服生物利用度和优异稳定性的推荐候选药物。